Rituximab, Bendamustine Hydrochloride, and Bortezomib Followed by Rituximab and Lenalidomide in Treating Older Patients With Previously Untreated Mantle Cell Lymphoma

NCT ID: NCT01415752

Last Updated: 2025-04-08

Basic Information

• Recruitment Status: ACTIVE_NOT_RECRUITING
• Clinical Phase: PHASE2
• Total Enrollment: 373 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2012-08-09
• Study Completion Date: 2031-09-30

Brief Summary

RATIONALE: Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some find cancer cells and help kill them or carry cancer-killing substances to them. Others interfere with the ability of cancer cells to grow and spread. Drugs used in chemotherapy, such as bendamustine hydrochloride, also work in different ways to kill cancer cells or stop them from dividing. Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Lenalidomide may stop the growth of mantle cell lymphoma by blocking blood flow to the cancer. It is not yet known whether giving rituximab together with bendamustine and bortezomib is more effective than rituximab and bendamustine, followed by rituximab alone or with lenalidomide in treating mantle cell lymphoma.

PURPOSE: This randomized phase II trial studies rituximab, bortezomib, bendamustine, and lenalidomide in treating previously untreated older patients with mantle cell lymphoma.

Detailed Description

OBJECTIVES:

Primary

• To determine whether the addition of bortezomib (RBV) to an induction regimen of rituximab-bendamustine (RB) improves progression-free survival (PFS) compared to RB alone in patients with previously untreated mantle cell lymphoma.
• To determine whether the addition of lenalidomide to a consolidation regimen of rituximab following an induction regimen of RB or RBV improves PFS compared to consolidation rituximab alone in this patient population.

Secondary

• To determine whether the addition of bortezomib to induction therapy improves the positron emission tomography (PET)-documented complete response (CR) rate compared to RB alone.
• To determine the objective response rate (ORR) for RB and RBV.
• Among patients who do not have PET-documented CR at the end of induction, to determine whether the addition of lenalidomide to consolidation therapy improves CR and ORR compared with rituximab alone.
• To determine overall survival (OS) in the treatment arms.
• To determine safety, with attention to the addition of bortezomib in the induction regimen and lenalidomide-rituximab (LR) as consolidation therapy.

Laboratory

• To collect paraffin-embedded tissue for creation of tissue microarray.
• To collect and bank serum and blood mononuclear cells for future studies.
• To collect formalin-fixed paraffin-embedded (FFPE) tissue to analyze potential prognostic factors (Ki-67 proliferation index by immunohistochemistry and correlation with proposed 5-gene set of proliferation markers analyzed by RNA PCR; SOX 11 expression by immunohistochemistry; and Micro-RNA levels by microarray).

Quality of Life

• Using patient-reported outcomes data, to determine the extent and severity of neuropathy associated with the addition of bortezomib to induction treatment.
• Using patient-reported outcomes data, to determine the extent and severity of fatigue associated with the addition of lenalidomide to consolidation treatment.
• To evaluate the effects of the addition of bortezomib and lenalidomide on patient-reported health-related quality of life.
• To evaluate the effects of bortezomib-related neuropathy on patient-reported health-related quality of life.
• To evaluate the response of lymphoma-specific symptoms to treatment.
• Using longitudinal patient-reported outcomes data, to describe the trajectory of lymphoma symptoms, neuropathy, fatigue, and overall health-related quality of life prior to, during, and following treatment among older adults with MCL.

Imaging

• To assess the proportion of patients up and down staging when fludeoxyglucose F 18- (FDG) PET/CT is added to standard Ann Arbor staging.
• To assess the ability of pre-treatment FDG-PET/CT (SUVmax) to predict response rate and PFS.
• Among patients with interim (post-cycle 3) FDG-PET/CT imaging, to assess the correlation of interim FDG-PET/CT imaging with response rate and PFS both during induction and consolidation therapy.
• To assess standard FDG-PET/CT metrics including SUVmax, tumor metabolic burden, total tumor burden, and association with pathology features (blastoid variant vs other, and Ki67) in the setting of MCL.
• To assess differences in overall and CR rates when using Deauville vs International Harmonization Project FDG-PET/CT interpretation criteria.
• To determine whether there is a correlation between FDG-PET/CT response and residual disease assessment by molecular and/or flow cytometric techniques.

Residual Disease Assessment by Molecular and Flow Cytometric Techniques

• To determine whether the number of malignant cells in circulation predict the number of cells in marrow.
• To determine whether the number of malignant cells in circulation/in marrow at the end of induction correlate with CR and 2-year PFS.
• To determine whether there is a higher rate of minimal residual disease (MRD) negativity among patients randomized to RBV as compared with RB, and among patients treated with LR maintenance compared with rituximab.
• To compare the two methods of MRD detection - molecular techniques and flow cytometry - as prognostic markers for outcome.

OUTLINE: This is a multicenter study. Patients are stratified according to mantle cell lymphoma International Prognostic Index risk score (low vs intermediate vs high). Patients are randomized to 1 of 4 treatment arms.

• Arm A: Patients receive induction therapy comprising rituximab IV on day 1 and bendamustine hydrochloride IV over 60 minutes on days 1-2. Treatment repeats every 4 weeks for 6 courses in the absence of disease progression or unacceptable toxicity.

• Arm E: Patients receive consolidation therapy comprising rituximab IV on day 1. Courses repeat every 8 weeks for 2 years in the absence of disease progression or unacceptable toxicity.
• Arm B: Patients receive induction therapy comprising bortezomib IV or subcutaneously (SC) on days 1, 4, 8, and 11 and rituximab and bendamustine hydrochloride as patients in arm A. Treatment repeats every 4 weeks for 6 courses in the absence of disease progression or unacceptable toxicity.

• Arm F: Patients receive consolidation therapy comprising rituximab IV on day 1. Courses repeat every 8 weeks for 2 years in the absence of disease progression or unacceptable toxicity.
• Arm C: Patients receive induction therapy comprising rituximab and bendamustine hydrochloride as patients in arm A. Treatment repeats every 4 weeks for 6 courses in the absence of disease progression or unacceptable toxicity.

• Arm G: Patients receive consolidation therapy comprising lenalidomide orally (PO) daily on days 1-21 every 4 weeks and rituximab IV every 8 weeks for 2 years in the absence of disease progression or unacceptable toxicity.
• Arm D: Patients receive bortezomib, rituximab, and bendamustine hydrochloride as patients in arm B. Treatment repeats every 4 weeks for 6 courses in the absence of disease progression or unacceptable toxicity.

• Arm H: Patients receive consolidation therapy comprising lenalidomide PO daily on days 1-21 every 4 weeks and rituximab IV every 8 weeks for 2 years in the absence of disease progression or unacceptable toxicity.

Patients may undergo blood and bone marrow sample collection at baseline and during treatment for correlative studies.

Patients complete the Functional Assessment of Cancer Therapy - Lymphoma (FACT-Lym), the FACT/GOG-Neurotoxicity scale (FACT/GOG-Ntx), FACT-Fatigue, and FACT-General questionnaires at baseline and periodically during study and follow up.

After completion of study treatment, patients are followed up every 3 months for 2 years, every 6 months for 3 years, and then annually for 10 years.

Conditions

Lymphoma; Mantle Cell Lymphoma

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Induction: (A) Bendamustine + Rituximab then Maintenance: (E) Rituximab

Patients receive induction therapy comprising rituximab IV on day 1 and bendamustine hydrochloride IV over 60 minutes on days 1-2. Treatment repeats every 4 weeks for 6 courses in the absence of disease progression or unacceptable toxicity. Patients then proceed to maintenance treatment.

Patients receive maintenance therapy comprising rituximab IV on day 1. Courses repeat every 8 weeks for 2 years in the absence of disease progression or unacceptable toxicity.

Group Type: EXPERIMENTAL

rituximab

Intervention Type: BIOLOGICAL

Given IV

Bendamustine

Intervention Type: DRUG

Given IV

Induction: (B) Bendamustine + Rituximab + Bortezomib then Maintenance: (F) Rituximab

Patients receive induction therapy comprising rituximab IV on day 1, bendamustine hydrochloride IV over 60 minutes on days 1-2 and bortezomib IV subcutaneously (SC) on days 1 and 8. Treatment repeats every 4 weeks for 6 courses in the absence of disease progression or unacceptable toxicity. Patients then proceed to maintenance treatment.

Patients receive maintenance therapy comprising rituximab IV on day 1. Courses repeat every 8 weeks for 2 years in the absence of disease progression or unacceptable toxicity.

Group Type: EXPERIMENTAL

rituximab

Intervention Type: BIOLOGICAL

Given IV

Bendamustine

Intervention Type: DRUG

Given IV

bortezomib

Intervention Type: DRUG

Given IV or SC

Induction: (C) Bendamustine + Rituximab then Maintenance: (G) Lenalidomide + Rituximab

Patients receive induction therapy comprising rituximab IV on day 1 and bendamustine hydrochloride IV over 60 minutes on days 1-2. Treatment repeats every 4 weeks for 6 courses in the absence of disease progression or unacceptable toxicity. Patients then proceed to maintenance treatment. Patients then proceed to maintenance treatment.

Patients receive maintenance therapy comprising lenalidomide orally (PO) daily on days 1-21 every 4 weeks and rituximab IV every 8 weeks for 2 years in the absence of disease progression or unacceptable toxicity.

Group Type: EXPERIMENTAL

rituximab

Intervention Type: BIOLOGICAL

Given IV

Bendamustine

Intervention Type: DRUG

Given IV

lenalidomide

Intervention Type: DRUG

Given PO

Induction: (D) Bendamustine + Rituximab + Bortezomib then Maintenance: (H) Lenalidomide + Rituximab

Patients receive induction therapy comprising rituximab IV on day 1, bendamustine hydrochloride IV over 60 minutes on days 1-2 and bortezomib IV subcutaneously (SC) on days 1 and 8. Treatment repeats every 4 weeks for 6 courses in the absence of disease progression or unacceptable toxicity. Patients then proceed to maintenance treatment.

Patients receive maintenance therapy comprising lenalidomide orally (PO) daily on days 1-21 every 4 weeks and rituximab IV every 8 weeks for 2 years in the absence of disease progression or unacceptable toxicity.

Group Type: EXPERIMENTAL

rituximab

Intervention Type: BIOLOGICAL

Given IV

Bendamustine

Intervention Type: DRUG

Given IV

bortezomib

Intervention Type: DRUG

Given IV or SC

lenalidomide

Intervention Type: DRUG

Given PO

Interventions

rituximab

Given IV

Intervention Type: BIOLOGICAL

Bendamustine

Given IV

Intervention Type: DRUG

bortezomib

Given IV or SC

Intervention Type: DRUG

lenalidomide

Given PO

Intervention Type: DRUG

Other Intervention Names

IDEC-C2B8; Chimeric anti-CD20 monoclonal antibody; Rituxan; bendamustine hydrochloride; CEP-18083; TREANDA; BENDEKA; MLN341; LDP-341; Velcade®; IMiDTM compound CC-5013; Revlimid®

Eligibility Criteria

Inclusion Criteria

• Mantle Cell Lymphoma International Prognostic Index (MIPI) score must be calculated and entered in OPEN
• Histologically confirmed untreated mantle cell lymphoma (MCL), with documented cyclin D1 by immunohistochemical stains and/or t(11;14) by cytogenetics or fluorescence in situ hybridization (FISH)
• Patients must have at least one objective measurable disease parameter
• Negative pregnancy test
• Women of childbearing potential and sexually active males use an accepted and effective method of contraception
• ECOG performance status 0-2
• Absolute neutrophil count (ANC) ≥ 1,500/mcL (1.5 x 10^9/L)
• Platelets ≥ 100,000/mcL (100 x 10^9/L)
• Aspartate transaminase (AST)/alanine transaminase (ALT) ≤ 2 times upper limit of normal (ULN)
• Bilirubin ≤ 2 times ULN
• Calculated creatinine clearance by Cockroft-Gault formula ≥ 30 mL/min
• Patient agrees that if randomized to Arms C or D, and proceeding onto Arms G or H, they must register into the mandatory RevAssist program, and be willing and able to comply with the requirements of RevAssist. Patients must have no medical contra-indications to, and be willing to take, DVT prophylaxis as all patients registering to the lenalidomide/rituximab Arms G and H will be required to have deep vein thrombosis (DVT) prophylaxis. Patients randomized to Arms G or H who have a history of a thrombotic vascular event will be required to have full anticoagulation, therapeutic doses of low molecular weight heparin or warfarin to maintain an INR between 2.0 - 3.0, or any other accepted full anticoagulation regimen (e.g. direct thrombin inhibitors or Factor Xa inhibitors) with appropriate monitoring for that agent. Patients on Arms G and H without a history of a thromboembolic event are required to take a daily aspirin (81 mg or 325 mg) for DVT prophylaxis. Patients who are unable to tolerate aspirin should receive low molecular weight heparin therapy or warfarin treatment or another accepted full anticoagulation regimen. Ways to minimize risk of DVT should be discussed with patients, including, but not limited to, avoiding smoking, minimizing prothrombotic hormone replacement, avoiding prolonged periods of inactivity (e.g. uninterrupted long car or plane trips).
• HIV-positive patients are not excluded but, to enroll, must meet all of the below criteria:

• HIV is sensitive to antiretroviral therapy
• Must be willing to take effective antiretroviral therapy, if indicated
• CD4 count at screening >= 300 cells/mm³
• If on antiretroviral therapy, must not be taking zidovudine or stavudine
• Must be willing to take prophylaxis for Pneumocystis jiroveci pneumonia (PCP) during therapy and until at least 2 months following the completion of therapy or until the CD4 cells recover to over 250 cells/mm³, whichever occurs later

• ECOG performance status between 0-2
• Complete response, partial response or stable disease after Step 1
• ANC >= 1000 cells/mm3 (1.0 x 10^9/L)
• Platelets >= 75,000 cells/mm3 (75 x 10^9/L)
• AST/ALT <= 2 x upper limit of normal (ULN)
• Total bilirubin <= 2 x upper limit of normal (ULN) or, if total elevated, direct bilirubin <= 2 x upper limit of normal (ULN)
• Calculated creatinine clearance by Cockroft-Gault formula >= 30 ml/min
• Patient agrees that if randomized to Arms C or D, and proceeding onto Arms G or H, they must register into the mandatory REMS program, and be willing and able to comply with the requirements of REMS.

• Pregnancy tests must occur within 10 - 14 days and again within 24 hours prior to initiation of Cycle 1 of lenalidomide.
• Females of childbearing potential (FCBP)* with regular or no menstruation must have a pregnancy test weekly for the first 28 days and then every 28 days while on lenalidomide therapy (including breaks in therapy); at discontinuation of lenalidomide and at Day 28 post the last dose of lenalidomide. Females with irregular menstruation must have a pregnancy test weekly for the first 28 days and then every 14 days while on lenalidomide therapy (including breaks in therapy), at discontinuation of lenalidomide and at Day 14 and Day 28 post the last dose of lenalidomide (see Appendix VI: Risks of Fetal Exposure, Pregnancy Testing Guidelines and Acceptable Birth Control Methods).
• Females of childbearing potential (FCBP)* must have a negative serum or urine pregnancy test with a sensitivity of at least 25 mIU/mL within 10 - 14 days and again within 24 hours prior to starting Cycle 1 of lenalidomide and must either commit to continued abstinence from heterosexual intercourse or begin TWO acceptable methods of birth control, one highly effective method and one additional effective method AT THE SAME TIME, at least 28 days before she starts taking lenalidomide. FCBP must also agree to ongoing pregnancy testing. Men must agree to use a latex condom during sexual contact with a FCBP even if they have had a successful vasectomy. All patients must be counseled at a minimum of every 28 days about pregnancy precautions and risks of fetal exposure.
• A female of childbearing potential is any sexually mature female, regardless of sexual orientation of whether they have undergone tubal ligation, who meets the following criteria: 1) has not undergone a hysterectomy or bilateral oophorectomy; or 2) has not been naturally postmenopausal (amenorrhea following cancer therapy does not rule out childbearing potential) for at least 24 consecutive months (i.e., has had menses at any time in the preceding 24 consecutive months).
• Females of childbearing potential (FCBP) must agree to use two reliable forms of contraception simultaneously or to practice complete abstinence from heterosexual intercourse during the following time periods related to this study/lenaliomide: 1) for at least 28 days before starting lenalidomide; 2) while participating in the study including interruptions in therapy; and 3) for at least 28 days after discontinuation/stopping lenalidomide. The two methods of reliable contraception must include one highly effective method (i.e. intrauterine device (IUD), hormonal [birth control pills, injections, or implants], tubal ligation, partner's vasectomy) and one additional effective (barrier) method (i.e. latex condom, diaphragm, cervical cap). FCBP must be referred to a qualified provider of contraceptive methods if needed.
• Women must agree to abstain from donating blood during study participation and for at least 28 days after discontinuation from protocol treatment.
• Males must agree to abstain from donating blood, semen, or sperm during study participation and for at least 28 days after discontinuation from protocol treatment. All males, regardless of whether they have undergone a successful vasectomy, must agree to use a latex condom during sexual contact with a female of childbearing potential, or to practice complete abstinence from heterosexual intercourse with any female of childbearing potential during all cycles of study treatment and for at least 28 days following discontinuation of protocol treatment
• Patients must have no medical contra-indications to, and be willing to take, DVT prophylaxis as all patients registering to the lenalidomide/rituximab Arms G and H will be required to have deep vein thrombosis (DVT) prophylaxis. Patients randomized to Arms G or H who have full anticoagulation, a history of a thrombotic vascular event will be required to have therapeutic doses of low molecular weight heparin or warfarin to maintain an INR between 2.0 - 3.0, or any other accepted full anticoagulation regimen (e.g. direct thrombin inhibitors or Factor Xa inhibitors) with appropriate monitoring for that agent. Patients on Arms G and H without a history of a thromboembolic event are required to take a daily aspirin (81 mg or 325 mg) for DVT prophylaxis. Patients who are unable to tolerate aspirin should receive low molecular weight heparin therapy or warfarin treatment or another accepted full anticoagulation regimen. Ways to minimize risk of DVT should be discussed with patients, including, but not limited to, avoiding smoking, minimizing pro-thrombotic hormone replacement, avoiding prolonged periods of inactivity (e.g. uninterrupted long car or plane trips).

Exclusion Criteria

• Women (sexually mature female) must not be pregnant or breast-feeding
• Evidence of prior malignancy except adequately treated non-melanoma skin cancer, in situ cervical carcinoma, low grade prostate carcinoma (Gleason grade ≤ 6) managed with observation that has been stable for at least 6 months, or any malignancy treated with curative intent continuously disease free for >=3 years so as not to interfere with interpretation of radiographic response
• Prior therapy for MCL, except: < 2 weeks of steroid therapy for symptom control or local radiation therapy for symptom control if there is measurable disease outside the radiation portal. Patients may be on chronic steroids for non-malignant disease if on a stable dose equivalent to ≤ 20 mg prednisone per day.
• CNS involvement
• History of AIDS-defining conditions
• Grade 2 or greater peripheral neuropathy.
• NYHA Class III or IV heart failure, uncontrolled angina severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute ischemia
• Hypersensitivity to bortezomib, boron or mannitol
• A serious medical or psychiatric illness likely to interfere with study participation
• Participating in any other therapeutic clinical trial or taking any other experimental medications within 14 days prior to registration.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 120 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

National Cancer Institute (NCI)

NIH

Sponsor Role: collaborator

Eastern Cooperative Oncology Group

NETWORK

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Mitchell R. Smith, MD, PhD

Role: PRINCIPAL_INVESTIGATOR

Fox Chase Cancer Center

Locations

Eastern Maine Medical Center

Bangor, Maine, United States

Alaska Breast Care and Surgery LLC

Anchorage, Alaska, United States

Alaska Women's Cancer Care

Anchorage, Alaska, United States

Anchorage Oncology Centre

Anchorage, Alaska, United States

Katmai Oncology Group

Anchorage, Alaska, United States

Providence Alaska Medical Center

Anchorage, Alaska, United States

Kaiser Permanente-Deer Valley Medical Center

Antioch, California, United States

Kaiser Permanente, Fremont

Fremont, California, United States

Kaiser Permanente

Fresno, California, United States

Los Angeles County-USC Medical Center

Los Angeles, California, United States

USC / Norris Comprehensive Cancer Center

Los Angeles, California, United States

Kaiser Permanente-Modesto

Modesto, California, United States

Kaiser Permanente-Oakland

Oakland, California, United States

Kaiser Permanente-Redwood City

Redwood City, California, United States

Kaiser Permanente-Richmond

Richmond, California, United States

Kaiser Permanente-Roseville

Roseville, California, United States

Kaiser Permanente-South Sacramento

Sacramento, California, United States

Kaiser Permanente - Sacramento

Sacramento, California, United States

Kaiser Permanente-San Francisco

San Francisco, California, United States

Kaiser Permanente-Santa Teresa-San Jose

San Jose, California, United States

Kaiser Permanente San Leandro

San Leandro, California, United States

Kaiser Permanente-San Rafael

San Rafael, California, United States

Kaiser Permanente Medical Center - Santa Clara

Santa Clara, California, United States

Kaiser Permanente-Santa Rosa

Santa Rosa, California, United States

Kaiser Permanente-South San Francisco

South San Francisco, California, United States

Stanford University Hospitals and Clinics

Stanford, California, United States

Kaiser Permanente-Stockton

Stockton, California, United States

Kaiser Permanente Medical Center-Vacaville

Vacaville, California, United States

Kaiser Permanente-Vallejo

Vallejo, California, United States

Kaiser Permanente-Walnut Creek

Walnut Creek, California, United States

Rocky Mountain Cancer Centers-Aurora

Aurora, Colorado, United States

The Medical Center of Aurora

Aurora, Colorado, United States

Boulder Community Hospital

Boulder, Colorado, United States

Rocky Mountain Cancer Centers-Boulder

Boulder, Colorado, United States

Penrose-Saint Francis Healthcare

Colorado Springs, Colorado, United States

Rocky Mountain Cancer Centers-Penrose

Colorado Springs, Colorado, United States

Kaiser Permanente-Franklin

Denver, Colorado, United States

Porter Adventist Hospital

Denver, Colorado, United States

Exempla Saint Joseph Hospital

Denver, Colorado, United States

Presbyterian - Saint Lukes Medical Center - Health One

Denver, Colorado, United States

Rocky Mountain Cancer Centers-Midtown

Denver, Colorado, United States

Rocky Mountain Cancer Centers-Rose

Denver, Colorado, United States

Rose Medical Center

Denver, Colorado, United States

Colorado Cancer Research Program CCOP

Denver, Colorado, United States

Colorado Blood Cancer Institute

Denver, Colorado, United States

Mercy Medical Center

Durango, Colorado, United States

Southwest Oncology PC

Durango, Colorado, United States

Comprehensive Cancer Care and Research Institute of Colorado LLC

Englewood, Colorado, United States

Swedish Medical Center

Englewood, Colorado, United States

Poudre Valley Hospital

Fort Collins, Colorado, United States

Mountain Blue Cancer Care Center

Golden, Colorado, United States

North Colorado Medical Center

Greeley, Colorado, United States

Rocky Mountain Cancer Centers-Greenwood Village

Greenwood Village, Colorado, United States

Kaiser Permanente-Rock Creek

Lafayette, Colorado, United States

Rocky Mountain Cancer Centers-Lakewood

Lakewood, Colorado, United States

Saint Anthony Hospital

Lakewood, Colorado, United States

Rocky Mountain Cancer Centers-Littleton

Littleton, Colorado, United States

Littleton Adventist Hospital

Littleton, Colorado, United States

Kaiser Permanente-Lone Tree

Lone Tree, Colorado, United States

Rocky Mountain Cancer Centers-Sky Ridge

Lone Tree, Colorado, United States

Sky Ridge Medical Center

Lone Tree, Colorado, United States

Longmont United Hospital

Longmont, Colorado, United States

Rocky Mountain Cancer Centers-Longmont

Longmont, Colorado, United States

McKee Medical Center

Loveland, Colorado, United States

Parker Adventist Hospital

Parker, Colorado, United States

Rocky Mountain Cancer Centers-Parker

Parker, Colorado, United States

Saint Mary Corwin Medical Center

Pueblo, Colorado, United States

Rocky Mountain Cancer Centers - Pueblo

Pueblo, Colorado, United States

Rocky Mountain Cancer Centers-Thornton

Thornton, Colorado, United States

Exempla Lutheran Medical Center

Wheat Ridge, Colorado, United States

Saint Francis Hospital and Medical Center

Hartford, Connecticut, United States

Beebe Medical Center

Lewes, Delaware, United States

Christiana Gynecologic Oncology LLC

Newark, Delaware, United States

Delaware Clinical and Laboratory Physicians PA

Newark, Delaware, United States

Helen F Graham Cancer Center

Newark, Delaware, United States

Medical Oncology Hematology Consultants PA

Newark, Delaware, United States

Regional Hematology and Oncology PA

Newark, Delaware, United States

Christiana Care Health System-Christiana Hospital

Newark, Delaware, United States

Beebe Health Campus

Rehoboth Beach, Delaware, United States

Nanticoke Memorial Hospital

Seaford, Delaware, United States

Christiana Care Health System-Wilmington Hospital

Wilmington, Delaware, United States

Lombardi Comprehensive Cancer Center at Georgetown University

Washington D.C., District of Columbia, United States

Baptist Cancer Institute

Jacksonville, Florida, United States

UF Cancer Center at Orlando Health

Orlando, Florida, United States

Oncare Hawaii Inc-POB II

Honolulu, Hawaii, United States

Queen's Medical Center

Honolulu, Hawaii, United States

Straub Clinic and Hospital

Honolulu, Hawaii, United States

University of Hawaii Cancer Center

Honolulu, Hawaii, United States

OnCare Hawaii-Liliha

Honolulu, Hawaii, United States

Oncare Hawaii Inc-Kuakini

Honolulu, Hawaii, United States

Kaiser Permanente Moanalua Medical Center

Honolulu, Hawaii, United States

Kapiolani Medical Center for Women and Children

Honolulu, Hawaii, United States

Castle Medical Center

Kailua, Hawaii, United States

Wilcox Memorial Hospital and Kauai Medical Clinic

Lihue, Hawaii, United States

Oncare Hawaii Inc-Pali Momi

‘Aiea, Hawaii, United States

Pali Momi Medical Center

‘Aiea, Hawaii, United States

Saint Alphonsus Cancer Care Center-Boise

Boise, Idaho, United States

Idaho Urologic Institute-Meridian

Meridian, Idaho, United States

Kootenai Cancer Center

Post Falls, Idaho, United States

Kootenai Cancer

Sandpoint, Idaho, United States

Memorial Hospital of Carbondale

Carbondale, Illinois, United States

Centralia Oncology Clinic

Centralia, Illinois, United States

Mount Sinai Hospital Medical Center

Chicago, Illinois, United States

Hematology and Oncology Associates

Chicago, Illinois, United States

Northwestern University

Chicago, Illinois, United States

John H Stroger Jr Hospital of Cook County

Chicago, Illinois, United States

Carle on Vermilion

Danville, Illinois, United States

Cancer Care Center of Decatur

Decatur, Illinois, United States

Decatur Memorial Hospital

Decatur, Illinois, United States

Carle Physician Group-Effingham

Effingham, Illinois, United States

Crossroads Cancer Center

Effingham, Illinois, United States

Hematology Oncology Associates of Illinois-Highland Park

Highland Park, Illinois, United States

Presence Saint Mary's Hospital

Kankakee, Illinois, United States

North Shore Hematology Oncology

Libertyville, Illinois, United States

Carle Physician Group-Mattoon/Charleston

Mattoon, Illinois, United States

Good Samaritan Regional Health Center

Mount Vernon, Illinois, United States

Illinois Cancer Specialists-Niles

Niles, Illinois, United States

SwedishAmerican Regional Cancer Center/ACT

Rockford, Illinois, United States

Hematology Oncology Associates of Illinois - Skokie

Skokie, Illinois, United States

Memorial Medical Center

Springfield, Illinois, United States

Carle Cancer Center

Urbana, Illinois, United States

The Carle Foundation Hospital

Urbana, Illinois, United States

IU Health Arnett Cancer Care

Lafayette, Indiana, United States

Franciscan Saint Anthony Health-Michigan City

Michigan City, Indiana, United States

Woodland Cancer Care Center

Michigan City, Indiana, United States

Reid Hospital and Health Care Services

Richmond, Indiana, United States

Mary Greeley Medical Center

Ames, Iowa, United States

McFarland Clinic PC-William R Bliss Cancer Center

Ames, Iowa, United States

Hematology Oncology Associates-Quad Cities

Bettendorf, Iowa, United States

McFarland Clinic PC-Boone

Boone, Iowa, United States

Cedar Rapids Oncology Association

Cedar Rapids, Iowa, United States

Mercy Hospital

Cedar Rapids, Iowa, United States

Oncology Associates at Mercy Medical Center

Cedar Rapids, Iowa, United States

McFarland Clinic PC-Trinity Cancer Center

Fort Dodge, Iowa, United States

McFarland Clinic PC-Jefferson

Jefferson, Iowa, United States

McFarland Clinic PC-Marshalltown

Marshalltown, Iowa, United States

Siouxland Hematology Oncology Associates

Sioux City, Iowa, United States

Mercy Medical Center-Sioux City

Sioux City, Iowa, United States

Saint Luke's Regional Medical Center

Sioux City, Iowa, United States

Lawrence Memorial Hospital

Lawrence, Kansas, United States

Menorah Medical Center

Overland Park, Kansas, United States

Saint Luke's South Hospital

Overland Park, Kansas, United States

Kansas City CCOP

Prairie Village, Kansas, United States

Wesley Medical Center

Wichita, Kansas, United States

Oncology Hematology Care Inc-Crestview

Crestview Hills, Kentucky, United States

Ochsner Health Center-Summa

Baton Rouge, Louisiana, United States

Ochsner Baptist Medical Center

New Orleans, Louisiana, United States

Ochsner Medical Center Jefferson

New Orleans, Louisiana, United States

Harold Alfond Center for Cancer Care

Augusta, Maine, United States

Penobscot Bay Medical Center

Rockport, Maine, United States

Franklin Square Hospital Center

Baltimore, Maryland, United States

Union Hospital of Cecil County

Elkton, Maryland, United States

Holy Cross Hospital

Silver Spring, Maryland, United States

Tufts Medical Center

Boston, Massachusetts, United States

Simonds-Sinon Regional Cancer Center

Fitchburg, Massachusetts, United States

Baystate Medical Center

Springfield, Massachusetts, United States

University of Massachusetts Medical School

Worcester, Massachusetts, United States

Saint Joseph Mercy Hospital

Ann Arbor, Michigan, United States

Michigan Cancer Research Consortium Community Clinical Oncology Program

Ann Arbor, Michigan, United States

Bronson Battle Creek

Battle Creek, Michigan, United States

Spectrum Health Big Rapids Hospital

Big Rapids, Michigan, United States

Oakwood Hospital and Medical Center

Dearborn, Michigan, United States

Wayne State University/Karmanos Cancer Institute

Detroit, Michigan, United States

Saint John Hospital and Medical Center

Detroit, Michigan, United States

Green Bay Oncology - Escanaba

Escanaba, Michigan, United States

Weisberg Cancer Treatment Center

Farmington Hills, Michigan, United States

Hurley Medical Center

Flint, Michigan, United States

Genesys Hurley Cancer Institute

Flint, Michigan, United States

Genesys Regional Medical Center

Grand Blanc, Michigan, United States

Grand Rapids Clinical Oncology Program

Grand Rapids, Michigan, United States

Mercy Health Saint Mary's

Grand Rapids, Michigan, United States

Spectrum Health at Butterworth Campus

Grand Rapids, Michigan, United States

Green Bay Oncology - Iron Mountain

Iron Mountain, Michigan, United States

Allegiance Health

Jackson, Michigan, United States

Borgess Medical Center

Kalamazoo, Michigan, United States

Bronson Methodist Hospital

Kalamazoo, Michigan, United States

West Michigan Cancer Center

Kalamazoo, Michigan, United States

Sparrow Hospital

Lansing, Michigan, United States

Saint Mary Mercy Hospital

Livonia, Michigan, United States

Mercy Health Mercy Campus

Muskegon, Michigan, United States

Lakeland Community Hospital

Niles, Michigan, United States

Saint Joseph Mercy Oakland

Pontiac, Michigan, United States

Saint Joseph Mercy Port Huron

Port Huron, Michigan, United States

Spectrum Health Reed City Hospital

Reed City, Michigan, United States

Saint Mary's of Michigan

Saginaw, Michigan, United States

Lakeland Hospital

Saint Joseph, Michigan, United States

Marie Yeager Cancer Center

Saint Joseph, Michigan, United States

Munson Medical Center

Traverse City, Michigan, United States

Saint John Macomb-Oakland Hospital

Warren, Michigan, United States

Sanford Clinic North-Bemidgi

Bemidji, Minnesota, United States

Fairview Ridges Hospital

Burnsville, Minnesota, United States

Mercy Hospital

Coon Rapids, Minnesota, United States

Essentia Health Cancer Center

Duluth, Minnesota, United States

Essentia Health Saint Mary's Medical Center

Duluth, Minnesota, United States

Miller-Dwan Hospital

Duluth, Minnesota, United States

Fairview-Southdale Hospital

Edina, Minnesota, United States

Unity Hospital

Fridley, Minnesota, United States

Hutchinson Area Health Care

Hutchinson, Minnesota, United States

Minnesota Oncology Hematology PA-Maplewood

Maplewood, Minnesota, United States

Saint John's Hospital - Healtheast

Maplewood, Minnesota, United States

Abbott-Northwestern Hospital

Minneapolis, Minnesota, United States

Hennepin County Medical Center

Minneapolis, Minnesota, United States

Health Partners Inc

Minneapolis, Minnesota, United States

New Ulm Medical Center

New Ulm, Minnesota, United States

North Memorial Medical Health Center

Robbinsdale, Minnesota, United States

Mayo Clinic

Rochester, Minnesota, United States

Metro-Minnesota CCOP

Saint Louis Park, Minnesota, United States

Park Nicollet Clinic - Saint Louis Park

Saint Louis Park, Minnesota, United States

Regions Hospital

Saint Paul, Minnesota, United States

United Hospital

Saint Paul, Minnesota, United States

Saint Francis Regional Medical Center

Shakopee, Minnesota, United States

Lakeview Hospital

Stillwater, Minnesota, United States

Ridgeview Medical Center

Waconia, Minnesota, United States

Rice Memorial Hospital

Willmar, Minnesota, United States

Minnesota Oncology and Hematology PA-Woodbury

Woodbury, Minnesota, United States

Parkland Health Center-Bonne Terre

Bonne Terre, Missouri, United States

Saint Francis Medical Center

Cape Girardeau, Missouri, United States

Southeast Cancer Center

Cape Girardeau, Missouri, United States

University of Missouri - Ellis Fischel

Columbia, Missouri, United States

Centerpoint Medical Center LLC

Independence, Missouri, United States

Capital Region Medical Center-Goldschmidt Cancer Center

Jefferson City, Missouri, United States

Freeman Health System

Joplin, Missouri, United States

Saint Luke's Hospital of Kansas City

Kansas City, Missouri, United States

Heartland Hematology and Oncology Associates Incorporated

Kansas City, Missouri, United States

Research Medical Center

Kansas City, Missouri, United States

Saint Luke's East - Lee's Summit

Lee's Summit, Missouri, United States

Liberty Radiation Oncology Center

Liberty, Missouri, United States

Phelps County Regional Medical Center

Rolla, Missouri, United States

Saint John's Clinic-Rolla-Cancer and Hematology

Rolla, Missouri, United States

Heartland Regional Medical Center

Saint Joseph, Missouri, United States

Mercy Hospital Springfield

Springfield, Missouri, United States

Ozark Health Ventures LLC-Cancer Research for The Ozarks Springfield

Springfield, Missouri, United States

CoxHealth South Hospital

Springfield, Missouri, United States

Saint Louis Cancer and Breast Institute-South City

St Louis, Missouri, United States

Washington University School of Medicine

St Louis, Missouri, United States

Missouri Baptist Medical Center

St Louis, Missouri, United States

Comprehensive Cancer Care PC

St Louis, Missouri, United States

Saint John's Mercy Medical Center

St Louis, Missouri, United States

Missouri Baptist Sullivan Hospital

Sullivan, Missouri, United States

Missouri Baptist Outpatient Center-Sunset Hills

Sunset Hills, Missouri, United States

Montana Cancer Consortium CCOP

Billings, Montana, United States

Saint Vincent Healthcare

Billings, Montana, United States

Frontier Cancer Center and Blood Institute-Billings

Billings, Montana, United States

Billings Clinic Cancer Center

Billings, Montana, United States

Bozeman Deaconess Hospital

Bozeman, Montana, United States

Saint James Community Hospital and Cancer Treatment Center

Butte, Montana, United States

Benefis Healthcare- Sletten Cancer Institute

Great Falls, Montana, United States

Great Falls Clinic

Great Falls, Montana, United States

Northern Montana Hospital

Havre, Montana, United States

Saint Peter's Community Hospital

Helena, Montana, United States

Glacier Oncology PLLC

Kalispell, Montana, United States

Kalispell Medical Oncology

Kalispell, Montana, United States

Kalispell Regional Medical Center

Kalispell, Montana, United States

Community Medical Hospital

Missoula, Montana, United States

Montana Cancer Specialists

Missoula, Montana, United States

Saint Patrick Hospital - Community Hospital

Missoula, Montana, United States

Dartmouth Hitchcock Medical Center

Lebanon, New Hampshire, United States

Norris Cotton Cancer Center Nashua

Nashua, New Hampshire, United States

Cooper Hospital University Medical Center

Camden, New Jersey, United States

Veterans Adminstration New Jersey Health Care System

East Orange, New Jersey, United States

Hematology Oncology Associates of Central New York-Auburn

Auburn, New York, United States

Hematology Oncology Associates of Central New York-East Syracuse

East Syracuse, New York, United States

Glens Falls Hospital

Glens Falls, New York, United States

Hematology Oncology Associates of Central New York-Liverpool

Liverpool, New York, United States

Orange Regional Medical Center

Middletown, New York, United States

Mount Sinai Medical Center

New York, New York, United States

Weill Medical College of Cornell University

New York, New York, United States

University of Rochester

Rochester, New York, United States

Hematology Oncology Associates of Central New York-Rome

Rome, New York, United States

Hematology Oncology Associates of Central New York-Onondaga Hill

Syracuse, New York, United States

Albert Einstein College of Medicine

The Bronx, New York, United States

Montefiore Medical Center - Moses Campus

The Bronx, New York, United States

Southeastern Medical Oncology Center-Clinton

Clinton, North Carolina, United States

Southeastern Medical Oncology Center-Goldsboro

Goldsboro, North Carolina, United States

Wayne Memorial Hospital

Goldsboro, North Carolina, United States

Hendersonville Hematology and Oncology at Pardee

Hendersonville, North Carolina, United States

Margaret R Pardee Memorial Hospital

Hendersonville, North Carolina, United States

Park Ridge Hospital Breast Health Center

Hendersonville, North Carolina, United States

Southeastern Medical Oncology Center-Jacksonville

Jacksonville, North Carolina, United States

Kinston Medical Specialists PA

Kinston, North Carolina, United States

Iredell Memorial Hospital

Statesville, North Carolina, United States

Southeastern Medical Oncology Center-Wilson

Wilson, North Carolina, United States

Wake Forest University Health Sciences

Winston-Salem, North Carolina, United States

Roger Maris Cancer Center

Fargo, North Dakota, United States

Sanford Clinic North-Fargo

Fargo, North Dakota, United States

Sanford Medical Center-Fargo

Fargo, North Dakota, United States

Summa Akron City Hospital/Cooper Cancer Center

Akron, Ohio, United States

Summa Barberton Hospital

Barberton, Ohio, United States

Cleveland Clinic Cancer Center Beachwood

Beachwood, Ohio, United States

Oncology Hematology Care Inc-Mercy West

Cincinnati, Ohio, United States

Oncology and Hematology Care Inc-Taft

Cincinnati, Ohio, United States

Oncology Hematology Care Inc - Anderson

Cincinnati, Ohio, United States

Oncology Hematology Care Inc - Kenwood

Cincinnati, Ohio, United States

Oncology Hematology Care Inc-Blue Ash

Cincinnati, Ohio, United States

University of Cincinnati

Cincinnati, Ohio, United States

Case Western Reserve University

Cleveland, Ohio, United States

MetroHealth Medical Center

Cleveland, Ohio, United States

Cleveland Clinic Cancer Center/Fairview Hospital

Cleveland, Ohio, United States

Cleveland Clinic Foundation

Cleveland, Ohio, United States

Arthur G. James Cancer Hospital and Solove Research Institute at Ohio State University Medical Center

Columbus, Ohio, United States

Grandview Hospital

Dayton, Ohio, United States

Good Samaritan Hospital - Dayton

Dayton, Ohio, United States

Miami Valley Hospital

Dayton, Ohio, United States

Samaritan North Health Center

Dayton, Ohio, United States

Dayton CCOP

Dayton, Ohio, United States

Mercy Cancer Center-Elyria

Elyria, Ohio, United States

Oncology Hematology Care Inc-Healthplex

Fairfield, Ohio, United States

Blanchard Valley Hospital

Findlay, Ohio, United States

Atrium Medical Center-Middletown Regional Hospital

Franklin, Ohio, United States

Wayne Hospital

Greenville, Ohio, United States

Cleveland Clinic Cancer Center Independence

Independence, Ohio, United States

Kettering Medical Center

Kettering, Ohio, United States

Cleveland Clinic Cancer Center Mansfield

Mansfield, Ohio, United States

Hillcrest Hospital Cancer Center

Mayfield Heights, Ohio, United States

Lake University Ireland Cancer Center

Mentor, Ohio, United States

North Coast Cancer Care

Sandusky, Ohio, United States

Cleveland Clinic Cancer Center Strongsville

Strongsville, Ohio, United States

Upper Valley Medical Center

Troy, Ohio, United States

South Pointe Hospital

Warrensville Heights, Ohio, United States

University Pointe

West Chester, Ohio, United States

UH-Seidman Cancer Center at Saint John Medical Center

Westlake, Ohio, United States

Cleveland Clinic Wooster Specialty Center

Wooster, Ohio, United States

Greene Memorial Hospital

Xenia, Ohio, United States

University of Oklahoma Health Sciences Center

Oklahoma City, Oklahoma, United States

Tulsa Cancer Institute

Tulsa, Oklahoma, United States

Clackamas Radiation Oncology Center

Clackamas, Oregon, United States

Providence Milwaukie Hospital

Milwaukie, Oregon, United States

Providence Newberg Medical Center

Newberg, Oregon, United States

Providence Willamette Falls Medical Center

Oregon City, Oregon, United States

Providence Portland Medical Center

Portland, Oregon, United States

Western Oncology Research Consortium

Portland, Oregon, United States

Providence Saint Vincent Medical Center

Portland, Oregon, United States

Geisinger Medical Center

Danville, Pennsylvania, United States

Geisinger Medical Center-Cancer Center Hazleton

Hazleton, Pennsylvania, United States

Geisinger Medical Oncology at Evangelical Community Hospital

Lewisburg, Pennsylvania, United States

Lewistown Hospital

Lewistown, Pennsylvania, United States

Fox Chase Cancer Center

Philadelphia, Pennsylvania, United States

Pottstown Memorial Medical Center

Pottstown, Pennsylvania, United States

Geisinger Medical Oncology-Pottsville

Pottsville, Pennsylvania, United States

Geisinger Medical Group

State College, Pennsylvania, United States

Mount Nittany Medical Center

State College, Pennsylvania, United States

Reading Hospital

West Reading, Pennsylvania, United States

Geisinger Wyoming Valley

Wilkes-Barre, Pennsylvania, United States

AnMed Health Cancer Center

Anderson, South Carolina, United States

Saint Francis Hospital

Greenville, South Carolina, United States

Gibbs Cancer Center-Pelham

Greer, South Carolina, United States

Spartanburg Regional Medical Center

Spartanburg, South Carolina, United States

Upstate Carolina CCOP

Spartanburg, South Carolina, United States

Wellmont Bristol Regional Medical Center

Bristol, Tennessee, United States

Wellmont Medical Associates Oncology and Hematology-Bristol

Bristol, Tennessee, United States

Wellmont Holston Valley Hospital and Medical Center

Kingsport, Tennessee, United States

Wellmont Medical Associates Oncology and Hematology-Kingsport

Kingsport, Tennessee, United States

Vanderbilt-Ingram Cancer Center

Nashville, Tennessee, United States

Parkland Memorial Hospital

Dallas, Texas, United States

University of Texas Southwestern Medical Center

Dallas, Texas, United States

University of Virginia

Charlottesville, Virginia, United States

Memorial Hospital Of Martinsville

Martinsville, Virginia, United States

Southwest VA Regional Cancer Center

Norton, Virginia, United States

Massey Cancer Center at Virginia Commonwealth University

Richmond, Virginia, United States

Kadlec Clinic Hematology and Oncology

Kennewick, Washington, United States

EvergreenHealth Medical Center

Kirkland, Washington, United States

Seattle Cancer Care Alliance at EvergreenHealth

Kirkland, Washington, United States

Saint John Medical Center

Longview, Washington, United States

Skagit Valley Hospital Regional Cancer Care Center

Mount Vernon, Washington, United States

Skagit Valley Hospital

Mount Vernon, Washington, United States

Olympic Medical Center

Port Angeles, Washington, United States

Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium

Seattle, Washington, United States

Seattle Cancer Care Alliance

Seattle, Washington, United States

University of Washington Medical Center

Seattle, Washington, United States

Olympic Medical Cancer Care Center

Sequim, Washington, United States

Cancer Care Northwest - Spokane South

Spokane, Washington, United States

Cancer Care Northwest-Valley

Spokane, Washington, United States

Cancer Care Northwest-North Spokane

Spokane, Washington, United States

PeaceHealth Southwest Medical Center

Vancouver, Washington, United States

Compass Oncology Vancouver

Vancouver, Washington, United States

Wenatchee Valley Hospital and Clinics

Wenatchee, Washington, United States

West Virginia University Healthcare

Morgantown, West Virginia, United States

Langlade Hospital and Cancer Center

Antigo, Wisconsin, United States

Marshfield Clinic Cancer Center at Sacred Heart

Eau Claire, Wisconsin, United States

Sacred Heart Hospital

Eau Claire, Wisconsin, United States

Agnesian Cancer Center

Fond du Lac, Wisconsin, United States

Green Bay Oncology at Saint Vincent Hospital

Green Bay, Wisconsin, United States

Saint Vincent Hospital

Green Bay, Wisconsin, United States

Green Bay Oncology Limited at Saint Mary's Hospital

Green Bay, Wisconsin, United States

Saint Mary's Hospital

Green Bay, Wisconsin, United States

UW Cancer Center Johnson Creek

Johnson Creek, Wisconsin, United States

Gundersen Lutheran Medical Center

La Crosse, Wisconsin, United States

University of Wisconsin Hospital and Clinics

Madison, Wisconsin, United States

Holy Family Memorial Hospital

Manitowoc, Wisconsin, United States

Bay Area Medical Center

Marinette, Wisconsin, United States

Marshfield Clinic

Marshfield, Wisconsin, United States

Saint Joseph's Hospital

Marshfield, Wisconsin, United States

Froedtert and the Medical College of Wisconsin

Milwaukee, Wisconsin, United States

Marshfield Clinic-Minocqua Center

Minocqua, Wisconsin, United States

D N Greenwald Center

Mukwonago, Wisconsin, United States

Cancer Center of Western Wisconsin

New Richmond, Wisconsin, United States

Oconomowoc Memorial Hospital-ProHealth Care Inc

Oconomowoc, Wisconsin, United States

Green Bay Oncology - Oconto Falls

Oconto Falls, Wisconsin, United States

Marshfield Clinic at James Beck Cancer Center

Rhinelander, Wisconsin, United States

Saint Mary's Hospital

Rhinelander, Wisconsin, United States

Marshfield Clinic-Rice Lake Center

Rice Lake, Wisconsin, United States

Saint Nicholas Hospital

Sheboygan, Wisconsin, United States

Marshfield Clinic Cancer Care at Saint Michael's Hospital

Stevens Point, Wisconsin, United States

Saint Michael's Hospital

Stevens Point, Wisconsin, United States

Green Bay Oncology - Sturgeon Bay

Sturgeon Bay, Wisconsin, United States

Waukesha Memorial Hospital - ProHealth Care

Waukesha, Wisconsin, United States

Aspirus Regional Cancer Center

Wausau, Wisconsin, United States

Marshfield Clinic-Wausau Center

Wausau, Wisconsin, United States

Diagnostic and Treatment Center

Weston, Wisconsin, United States

Marshfield Clinic - Weston Center

Weston, Wisconsin, United States

Saint Clare's Hospital

Weston, Wisconsin, United States

Marshfield Clinic - Wisconsin Rapids Center

Wisconsin Rapids, Wisconsin, United States

Rocky Mountain Oncology

Casper, Wyoming, United States

Big Horn Basin Cancer Center

Cody, Wyoming, United States

Billings Clinic-Cody

Cody, Wyoming, United States

Welch Cancer Center

Sheridan, Wyoming, United States

The Moncton Hospital

Moncton, New Brunswick, Canada

Allan Blair Cancer Centre

Regina, Saskatchewan, Canada

Countries

United States; Canada

References

Smith MR, Jegede OA, Martin P, Till BG, Parekh SS, Yang DT, Hsi ED, Witzig T, Dave S, Scott D, Hanson C, Kostakoglu Shields L, Abdel-Samad N, Casulo C, Bartlett NL, Caimi PF, Al Baghdadi T, Blum KA, Romer MD, Inwards DJ, Lerner RE, Wagner LI, Little RF, Friedberg JW, Leonard JP, Kahl BS. Randomized study of induction with bendamustine-rituximab +/- bortezomib and maintenance with rituximab +/- lenalidomide for MCL. Blood. 2024 Sep 5;144(10):1083-1092. doi: 10.1182/blood.2024023962.

Reference Type: RESULT

PMID: 38820500 (View on PubMed)

Provided Documents

Document Type: Study Protocol and Statistical Analysis Plan

View Document

Other Identifiers

NCI-2011-02980

Identifier Type: OTHER

Identifier Source: secondary_id

CDR0000707057

Identifier Type: OTHER

Identifier Source: secondary_id

E1411

Identifier Type: -

Identifier Source: org_study_id